ARTICLE | Clinical News
Oxypurinol: Phase II data
August 22, 2005 7:00 AM UTC
Data from the double-blind, placebo-controlled, North American Phase II OPT-CHF trial in 405 patients showed that oral oxypurinol missed the primary composite endpoint (p=0.357). Also, no benefits wer...